AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Venclexta (venetoclax) by Quarter
Venclexta (venetoclax) — International net revenues ($M) ($M)
AbbVie Venclexta (venetoclax): $402M in Q2 2026, up 8.6% from a year earlier.
Latest, Q2 2026
402
Period ended Jun 30, 2026
Change on a year earlier
+8.6%
370 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
31
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up venclexta (venetoclax)
Cite this data
StockData. (2026). AbbVie Venclexta (venetoclax) ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/venclexta-intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.